Highest-materiality recent filing
BD resumes ChloraPrep shipments after voluntary hold; all final release testing acceptable
BD voluntarily placed ChloraPrep and PurPrep on ship hold on May 6, 2026 for additional final release testing.
BD subsidiary issues €600M 3.855% Notes due 2033; proceeds to repay near-term debt
€600M aggregate principal of 3.855% Notes due May 20, 2033 issued by BD indirect sub Becton Finance.
BD launches €600M 3.855% notes due 2033 to refinance maturing Euro notes
€600M aggregate principal of 3.855% Notes due 2033, guaranteed by BD.
BD appoints Vitor Roque as EVP and CFO effective May 7; compensation disclosed
Roque named EVP and CFO effective May 7, 2026; served as interim CFO since December 2025.
Revenue $4,714M, +5.2% reported/2.6% FX-neutral; GAAP diluted EPS $(0.13) from continuing ops vs $0.55 prior year.
BDX board approves bylaw amendments updating advance notice provisions and technical revisions
Board approved amended and restated By-laws on April 28, 2026.
BD EVP & Interventional President Richard Byrd to retire in June 2026
Richard Byrd, EVP and President of Interventional segment, will retire after nearly 25 years at BD; will stay in role through June.
BD files recast financials to reflect Feb 2026 spin-off of Biosciences & Diagnostics
Recast historical data presents continuing operations only, excluding the spun-off Biosciences and Diagnostic Solutions business.
BD upsizes senior notes tender to $2B, announces early results and pricing
Upsized aggregate offer cap from $1.6B to $2.0B; early tenders exceeded cap, triggering proration on 3.794% notes due 2050.
BD launches $1.6B tender offers for 15 series of senior notes
Up to $1.6B aggregate purchase price (excluding accrued interest) for 15 series of senior notes maturing 2026-2050.
BD completes spin-off of Biosciences & Diagnostic Solutions business and combination with Waters
BD completed spin-off of Biosciences & Diagnostic Solutions business and combination with Waters, receiving $4 billion cash.
BD Q1 revenue $5.25B beats; closes Waters deal; affirms FY26 guidance
Revenue $5.252B (+1.6% reported, +0.4% FX neutral); GAAP EPS $1.34, adjusted EPS $2.91.
Filed Certificate of Designation for Series D Junior Participating Redeemable Preferred Stock.
BD reorganizes into five segments; provides recast historical revenue data
New segments effective Oct 1, 2025: Medical Essentials, Connected Care, BioPharma Systems, Interventional, Life Sciences.
BD adopts executive severance plan; shareholders approve equity plan increase
Severance Plan adopted: CEO gets 1.5x base+bonus, ELT 1.0x, Business Unit Presidents 1.0x base.
BD 401(k) Plan enters blackout period pending Waters Corp transaction close
Blackout begins after market close on closing date of pending Waters Corp transaction.
BDX amends 8-K to disclose director compensation for Huffines and Wright
Robert L. Huffines and Jacqueline Wright elected to BD Board, effective Dec 1, 2025.
BD elects Robert Huffines and Jacqueline Wright to board, effective Dec 1, 2025
Board expands from 12 to 14 members; both new directors deemed independent under NYSE rules.
BD Q4 revenue $5.9B (+8.3%); FY25 adjusted EPS $14.40 (+9.6%); FY26 guidance
Q4 revenue $5,890M, up 8.3% as reported, 3.9% organic; GAAP EPS $1.72, adjusted EPS $3.96.
BD reports prelim Q4 rev $5.9B (+8.3%); CFO DelOrefice to depart Dec 5; Roque interim CFO
Preliminary Q4 revenue ~$5.9B, up 8.3% reported, 3.9% organic; FY revenue ~$21.8B, up 8.2% reported, 2.9% organic.
BDX enters into $2.75B revolving credit facility due 2030
$2.75B senior unsecured revolving credit facility, with $100M letter of credit and $236M swingline subfacilities.
BD Q3 revenue $5.5B (+10.4%); adjusted EPS $3.68; raises FY guidance to $14.30-$14.45
Revenue of $5.5B, up 10.4% as reported and 3.0% organic; GAAP EPS $2.00, adjusted EPS $3.68.
BD to combine its Biosciences & Diagnostic Solutions with Waters in ~$17.5B RMT transaction
Transaction valued at ~$17.5B; BD shareholders to own ~39.2% of combined company; Waters ~60.8%.
BD to spin off Biosciences/Diagnostics, merge with Waters for $4B cash plus 39.2% stake
BD receives $4B cash from SpinCo; BD shareholders get 39.2% of Waters post-merger; Waters holders get 60.8%.
BD settles derivative suit for $9M from D&O insurance; adopts governance changes
D&O insurers will pay $9M to BD to settle derivative claims over Alaris pump disclosures.
BDX amends by-laws to update advance notice requirements for shareholder nominations and business
Amended Article II, Section 2.D. to revise procedural and disclosure requirements for nominations and other business at annual meetings.
BD Q2 fiscal 2025: Revenue $5.27B (+4.5%), GAAP EPS $1.07 (down 42% YoY), adj. EPS $3.35
Revenue increased 4.5% as reported to $5.272B; organic growth 0.9%, currency-neutral growth 6.0%.
BD elects Gregory J. Hayes to Board of Directors
Effective March 26, 2025, Gregory J. Hayes elected to BD's Board, expanding size from 11 to 12 members.
BD beats Q1 estimates, announces plan to separate Biosciences and Diagnostic Solutions
Q1 revenue $5.2B (+9.8% reported, +3.9% organic); adj. EPS $3.43 (+28.0% YoY); GAAP EPS $1.04.
BD shareholders elect all 11 director nominees, ratify EY, approve say-on-pay
All 11 director nominees elected with >90% support; highest vote for Carrie L. Byington (233.5M for).
BD appoints Pamela Spikner as Chief Accounting Officer and Controller effective Jan 20, 2025
Pamela Spikner named SVP, Chief Accounting Officer and Controller, effective January 20, 2025.
Q4 revenue $5.4B, +6.9% as reported; GAAP EPS $1.45 (vs $0.53), adjusted EPS $3.81 (vs $3.42).
Settlement covers cases in Rhode Island consolidated litigation and federal MDL in Ohio; no admission of liability.
BDX reassigns Thomas Spoerel to SVP, CFO Regions; DelOrefice interim principal accounting officer
Effective Aug. 30, 2024, Thomas Spoerel becomes SVP, CFO Regions, leading finance integration for Edwards Critical Care acquisition.
BD Q3 adjusted EPS $3.50 beats, raises FY24 guidance; acquires Edwards Critical Care for $4.2B
Revenue $4.99B as reported, $5.057B adjusted; organic revenue growth 5.2% YoY.
Becton Dickinson extends $2.75B revolving credit facility maturity to September 2027
Lenders consented to one-year extension of commitment termination date to September 24, 2027.
BD issues €1.8B + $600M notes to fund Edwards Critical Care acquisition
€1.0B 3.828% notes due 2032, €800M 4.029% notes due 2036, $600M 5.081% notes due 2029 issued June 7.
BD to acquire Edwards Lifesciences' Critical Care for $4.2B in cash
Acquisition price of $4.2B in cash; expected to close by end of calendar 2024, subject to regulatory approvals.
BD Q2 revenue $5.0B (+4.6%), adj. EPS $3.17 (+10.8%); raises FY24 adjusted EPS guidance
Q2 revenue $5,045M (+4.6% reported, +5.7% organic); GAAP diluted EPS $1.85 (+20.9%), adjusted EPS $3.17 (+10.8%).
BD Life Sciences President Dave Hickey to retire effective July 1, 2024
Dave Hickey, EVP and President of Life Sciences segment, announced retirement effective July 1, 2024.
BD issues €750M 3.519% notes and $1.175B USD notes (4.874%/5.110%) to refinance 2024 debt
Issued €750M 3.519% Notes due Feb 8, 2031 in underwritten public offering.
BD issues $1.175B USD notes and €750M EUR notes to refinance 2024 maturities
$625M 4.874% notes due 2029 and $550M 5.110% notes due 2034 issued in USD offering.
BD Q1 revenue $4.7B (+2.6% YoY), GAAP EPS $0.96, adj. EPS $2.68; raises FY2024 guide
Q1 revenue $4,706M, up 2.6% as reported, 2.4% organic; currency-neutral growth 1.6%.
BD shareholders elect all 11 director nominees, ratify auditor, approve say-on-pay
All 11 board nominees elected with majority support; highest vote For: Joanne Waldstreicher (238.3M), lowest: Jeffrey Henderson (217.3M).
BD files settlement docs for $85M class action over infusion pump statements
Settlement of $85M to resolve class action claims against BD and officers; no admission of liability.
Policy prohibits new executive severance agreements exceeding 2.99 times base salary plus target bonus unless shareholder ratified.
BD Q4 revenue $5.1B up 6.8%; adjusted EPS $3.42 beats; guides FY24 organic growth 5.75%
Q4 revenue of $5.1B, +6.8% as reported, +5.9% currency-neutral; base business organic growth 7.0%.
BDX amends bylaws to tighten advance-notice rules for shareholder nominations and proposals
Amended By-laws effective Sept 19, 2023, enhance disclosure requirements for director nominations and proposals.
BD Q3 revenue $4.88B up 5.1%, adjusted EPS $2.96 up 11.3%, raises FY revenue guidance
Revenue of $4.88B, up 5.1% as reported, 6.3% currency-neutral; base revenue growth 6.7% as reported.
BD elects Dr. Joanne Waldstreicher to Board of Directors
Dr. Waldstreicher elected effective July 24, 2023; will serve on Corporate Governance and Nominating, and Quality and Regulatory committees.
Effective May 7, 2026 (the “Effective Date”), the Company’s Board of Directors (the “Board”) approved the appointment of Mr. Roque as the Company’s Executive Vice President and Chief Financial Officer.
Effective March 26, 2025, Gregory J. Hayes was elected to the Board of Directors (the “Board”) of Becton, Dickinson and Company (“BD”).
On January 9, 2025, the Board of Directors (the “Board”) of Becton, Dickinson and Company (the “Company”) appointed Pamela L. Spikner as Senior Vice President, Chief Accounting Officer and Controller, effective January 20, 2025.
Christopher DelOrefice, Executive Vice President and Chief Financial Officer, will assume the responsibilities of principal accounting officer on an interim basis.
Thomas Spoerel will serve as the Senior Vice President, CFO Regions along with finance leadership for the finance integration of the recently announced agreement for Becton Dickinson to acquire the Edwards Life Sciences’ Critical Care product group.
On February 22, 2024, David Hickey, Executive Vice President and President of the Life Sciences segment of Becton, Dickinson and Company ("BD"), informed BD of his intention to retire, effective July 1, 2024.
On July 24, 2023, Dr. Joanne Waldstreicher was elected to the Board of Directors of Becton, Dickinson and Company.
On December 30, 2022, Samrat S. Khichi, Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel, informed BD of his intent to depart BD for a new opportunity, effective February 3, 2023.
Michael Garrison has been named BD's Executive Vice President and President, Medical Segment
Richard Byrd has been named BD's Executive Vice President and President, Interventional Segment
Simon Campion informed BD that he will depart BD on September 9, 2022 for an executive role in the health care industry.
each of Claire Pomeroy, MD and David F. Melcher has resigned as directors of BD, in each case effective as of April 1, 2022, in connection with the completion of the Separation and the Distribution and their appointment to the board of directors of embecta.
Max materiality 1.00 · Median 0.60 · Most common event earnings